News
SNDX
--
0.00%
--
Is Syndax Pharmaceuticals (NASDAQ:SNDX) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Simply Wall St. · 09/03 19:51
Syndax Announces Participation at Three Upcoming Investor Conferences
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual
PR Newswire · 09/02 12:00
Syndax Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 08/07 14:33
Syndax Pharmaceuticals EPS beats by $0.05, revenue in-line
Syndax Pharmaceuticals (NASDAQ:SNDX): Q2 GAAP EPS of -$0.42 beats by $0.05. Revenue of $0.39M in-line (flat Y/Y). Press Release
seekingalpha · 08/07 01:27
Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2020. In
PR Newswire · 08/06 20:05
Did Hedge Funds Make The Right Call On Syndax Pharmaceuticals, Inc. (SNDX) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 08/04 15:13
Syndax Announces Participation in BTIG Virtual Biotechnology Conference
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate virtually in th
PR Newswire · 08/03 11:00
Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial results on Th
PR Newswire · 07/30 11:00
Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer
PR Newswire · 07/07 12:00
Syndax Pharmaceuticals Appoints Daphne Karydas As Chief Financial Officer
Benzinga · 07/07 11:14
Hedge Funds Have Never Been This Bullish On Syndax Pharmaceuticals, Inc. (SNDX)
Insider Monkey · 06/24 00:27
Edited Transcript of SNDX earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/10 05:14
Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352
Seeking Alpha - Article · 06/09 10:13
Morgan Stanley Maintains Equal-Weight on Syndax Pharmaceuticals, Lowers Price Target to $16
Morgan Stanley maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Equal-Weight and lowers the price target from $22 to $16.
Benzinga · 06/01 14:08
Morgan Stanley Maintains Equal-Weight on Syndax Pharmaceuticals, Lowers Price Target to $16
Morgan Stanley maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Equal-Weight and lowers the price target from $22 to $16.
Benzinga · 05/29 12:30
Aurinia Files NDA, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/29 02:52
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 05/26 08:30
Does Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Have A Particularly Volatile Share Price?
Simply Wall St. · 05/25 20:17
Mid-Afternoon Market Update: NASDAQ Turns Higher; Hewlett Packard Shares Tumble
Toward the end of trading Friday, the Dow traded down 0.14% to 24,440.10 while the NASDAQ rose 0.40% to 9,322.26. The S&P also rose, gaining 0.16% to 9,322.26.
Benzinga · 05/22 18:47
Syndax Pharma's entinostat comes up empty again in breast cancer study
A National Cancer Institute-conducted Phase 3 clinical trial, E2112, evaluating Pfizer's (NYSE:PFE) Aromasin (exemestane), with or without Syndax Pharmaceu
seekingalpha · 05/22 17:40